Fulgent Genetics, Inc. Provides Revenue Guidance for the Fourth Quarter of 2021
November 09, 2021 at 09:05 pm
Share
Fulgent Genetics, Inc. provided revenue guidance for the fourth quarter of 2021. For the quarter, the company expects revenue to be approximately $189 million and core Revenue of approximately $32 million, representing growth of 166% year-over-year.
Fulgent Genetics, Inc. is a technology-based genetic company with a laboratory services business and a therapeutic development business. The Companyâs laboratory services business includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile (PK) profile of new and existing cancer drugs. Its technology platform for its laboratory services business includes gene probes, data suppression and comparison algorithms, learning software, and laboratory information management systems. The platform provides a test menu, the ability to rapidly develop and launch new tests and customizable test offerings. The Company also offers next-generation sequencing (NGS) services.
FULGENT GENETICS, INC. 
